Madrigal Pharmaceuticals (MDGL) Short-term Investments (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Short-term Investments data on file, last reported at $5.2 million in Q1 2026.

• On a quarterly basis, Short-term Investments fell 99.21% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 99.21% decrease from a year earlier, with the FY2025 full-year figure at $784.9 million, up 15597.32% from the prior year.
• Short-term Investments for Q1 2026 stood at $5.2 million, down from $784.9 million in the prior quarter.
• Over the last five years, Short-term Investments for MDGL reached as high as $814.1 million in Q3 2025 and fell as low as $5.0 million in Q4 2024.
• Historically, Short-term Investments has averaged $367.3 million across 5 years, with a median of $221.2 million in 2023.
• Across the five-year window, Short-term Investments surged 15597.32% in 2025 and slumped 99.21% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $27.2 million in 2022, then surged by 1862.23% to $534.2 million in 2023, then slumped by 99.06% to $5.0 million in 2024, then jumped by 15597.32% to $784.9 million in 2025, then plunged by 99.34% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $5.2 million in Q1 2026, $784.9 million in Q4 2025, and $814.1 million in Q3 2025.